Gink­go Bioworks hand­ed a DARPA man­u­fac­tur­ing con­tract; Mer­ck hits a pri­ma­ry end­point for Keytru­da in first-line cer­vi­cal can­cer

The De­fense Ad­vanced Re­search Projects Agency (DARPA) is giv­ing Gink­go Bioworks a 4-year con­tract worth up to $18 mil­lion, to man­u­fac­ture com­plex ther­a­peu­tic pro­teins.

Gink­go is part of DARPA’s “Reimag­in­ing Pro­tein Man­u­fac­tur­ing project,” which is de­signed to help the DOD get ac­cess to pro­teins more quick­ly. Gink­go plans to man­u­fac­ture pro­teins faster by us­ing its “cell-free pro­tein syn­the­sis to en­able rapid, high-yield” pro­duc­tion of pro­teins for na­tion­al se­cu­ri­ty ini­tia­tives.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER